AM-37 and ST-36 Are Small Molecule Bombesin Receptor Antagonists

Terry W. Moody1*, Nicole Tashakkori1, Samuel A. Mantey2, Paola Moreno2, Irene Ramos-Alvarez2, Marcello Leopoldo3 and Robert T. Jensen2

1Department of Health and Human Services, National Cancer Institute, Center for Cancer Research, Bethesda, MD, United States, 2National Institute of Diabetes, Digestive and Kidney Disease, Digestive Diseases Branch, Bethesda, MD, United States, 3Dipartimento di Farmacia, Scienze del Farmaco, Università degli Studi di Bari Aldo Moro, Bari, Italy

While peptide antagonists for the gastrin-releasing peptide receptor (BB2R), neuromedin B receptor (BB-R), and bombesin (BB) receptor subtype-3 (BRS-3) exist, there is a need to develop non-peptide small molecule inhibitors for all three BBR. The BB agonist (BA)1 binds with high affinity to the BB-R, BB2R, and BRS-3. In this communication, small molecule BBR antagonists were evaluated using human lung cancer cells. AM-37 and ST-36 inhibited binding to human BB1R, BB2R, and BRS-3 with similar affinity (Ki = 1.4–10.8 µM). AM-13 and AM-14 were approximately an order of magnitude less potent than AM-37 and ST-36. The ability of BA1 to elevate cytosolic Ca2+ in human lung cancer cells transfected with BB1R, BB2R, and BRS-3 was antagonized by AM-37 and ST-36. BA1 increased tyrosine phosphorylation of the EGFR and ERK in lung cancer cells, which was blocked by AM-37 and ST-36. AM-37 and ST-36 reduced the growth of lung cancer cells that have BBR. The results indicate that AM-37 and ST-36 function as small molecule BB receptor antagonists.

Keywords: small molecule antagonists, GRPR, NMBR, bombesin receptor subtype-3, lung cancer

INTRODUCTION

The bombesin (BB) family of peptides is biologically active in the central nervous system (CNS) and periphery. BB, a 14 amino acid peptide isolated from frog skin, has 9 of the 10 same C-terminal amino acids as does human gastrin-releasing peptide (GRP), a 27 amino acid peptide (1). GRP binds with high affinity to the BB-R, which regulates pruritus, lung development, and gastrin secretion. Neuromedin B (NMB) is a 10 amino acid peptide with 70% sequence homology to the C-terminal of BB. NMB binds with high affinity to the BB-R and causes satiety, hypothermia, and thyrotropin (TSH) secretion from the pituitary (2). BB receptor subtype-3 (BRS-3) is an orphan receptor with homology to the BB-R and BB2R, and binds the universal agonist, BB agonist (BA)1, with high affinity as does the BB-R and BB2R (3). Because BRS-3 knockout mice have impaired energy balance, glucose homeostasis, and increased body weight, BRS-3 agonists may function as satiety agents (4).

In the CNS, GRP and NMB may act in a paracrine manner being released from brain neurons in the hypothalamus and dentate gyrus, respectively, activating BB-R and BB2R in adjacent cells (5).

In numerous cancers, including lung cancer, GRP and NMB function in an autocrine manner to stimulate cellular proliferation. Small cell lung cancer (SCLC), a neuroendocrine tumor, has high levels of GRP (6, 7). GRP is secreted from SCLC and binds to cell surface BB-R resulting in increased cellular proliferation (8). NMB is present in both SCLC and non-small cell lung cancer (NSCLC) cells, and after secretion it binds to cell surface BB-R stimulating proliferation (9). Because...
many lung cancer cells have BB₁, BB₂, and/or BRS-3 there is a need to develop antagonists that block all three receptors of the BB family.

The human BB₁, BB₂, and BRS-3 contain 390, 384, and 399 amino acids and have approximately 50% sequence homology. The BB₁, BB₂, and BRS-3 are members of the rhodopsin β group G protein-coupled receptors (GPCR) family, and they interact with Gq causing phosphatidylinositol (PI) turnover (10). PI-4,5-bisphosphate (PIP₂) is metabolized to diacylglycerol, which activates protein kinase C and inositol-trisphosphate (IP₃) which causes elevated cytosolic Ca²⁺. Neuropeptide receptors regulate the transactivation of the epidermal growth factor (EGF) receptor leading to NSCLC proliferation (11). The proliferation of NSCLC cells caused by BA₁ can be inhibited by the tyrosine kinase inhibitor (TKI) gefitinib or BBR antagonists. The actions of BA₁ on BB₁, BB₂, and BRS-3 are antagonized selectively by various concentrations of AM-37, ST-36, AM-13, or AM-14 followed by 10 nM BA₁.

In the present study, small molecules were synthesized and their ability to antagonize BB₁, BB₂, and BRS-3 in lung cancer cells evaluated. The results indicate that AM-37 and ST-36 are useful agents to inhibit the growth of NSCLC cells which have BB₁, BB₂, or BRS-3.

**MATERIALS AND METHODS**

**Cell Culture**

Non-small cell lung cancer cell line NCI-H1299 (ATCC, Manassas, VA, USA) was stably transfected with BB₁, BB₂, and BRS-3. The transfected cells were grown in RPMI-1640 containing 10% fetal bovine serum (FBS) with 0.3 mg/ml gentamicin (Invitrogen, Grand Island, NY, USA). The transfected cells, which contained approximately 100,000 receptors/cell, were weekly split using trypsin/EDTA (13). In addition, lung cancer cell lines NCI-H727, H1299, and H1975 were purchased from ATCC and cultured in RPMI-1640, which contained 10% FBS. The cell types were derived from different human biopsy specimens. These studies were approved by the NIDDK biospecimens and biosafety committees.

**Ligand Synthesis**

The small molecules were synthesized as described previously (14). Figure 1D shows the structural formula of AM-37, (R)-3-[(1H-indol-3-yl)-2-[3-(4-methoxyphenyl)ureido]-N-[[1-(3-pyridinyl)cyclohexyl]methyl]propanamide, and of its S-enantiomer ST-36. Figure 1E shows the structural formula of AM-13, (R)-N-[1-(4-fluorophenyl)cyclohexyl][methyl]-3-[(1H-indol-3-yl)-2-[3-(4-methoxyphenyl)ureido]propanamide, and its S-enantiomer AM-14. The molecular weight of AM-37 and ST-36 is 525.6 Da, whereas the molecular weight of AM-13 and AM-14 is 542.2 Da.

**Receptor Binding**

The ability of AM-37, ST-36, AM-13, and AM-14 to inhibit specific ¹²⁵I-BA₁ binding to NSCLC cells transfected stably with BB₁, BB₂, and BRS-3 was investigated. NSCLC cells were placed in 24 well plates. When confluent, the cells were washed three times with PBS. The cells were incubated with binding buffer (PBS containing 0.25% bovine serum albumin and 0.025% bacitracin, Sigma-Aldrich, St. Louis, MO, USA). Various concentrations of AM-37, ST-36, AM-13, or AM-14 were added to the cells for 10 min, followed by 100,000 cpm of ¹²⁵I-BA₁ (0.16 nM) and incubated at 37°C for 30 min when equilibrium of binding was reached. The cells were rinsed three times with binding buffer for 2 min at 4°C. The cells that contained bound peptide dissolved in 0.2 N NaOH and counted in a Wallac 1470 γ-counter. The Kᵢ was calculated as described (15).

**Cytosolic Ca²⁺**

The ability of AM-37, ST-36, AM-13, and AM-14 to function as BBR antagonists was investigated. NSCLC cells transfected with BB₁, BB₂, and BRS-3 were harvested and loaded with Fura-2AM (Calbiochem, La Jolla, CA, USA) as described previously (16). The excitation ratio was determined at 340 and 380 nm with an emission wavelength of 510 nm. The lung cancer cellular calcium response was determined after the addition of AM-37, ST-36, AM-13, or AM-14 followed by 10 nM BA₁.

**Tyrosine Phosphorylation**

The tyrosine phosphorylation of the EGFR and ERK was investigated by western blot. NSCLC cells transfected with BB₁, BB₂, and BRS-3 were placed in 10 cm dishes. When the cells were confluent, they were placed in SIT medium (RPMI-1640 containing 3 × 10⁻⁸ M sodium selenite, 5 μg/ml bovine insulin, and 10 μg/ml apo-transferrin; Sigma-Aldrich, St. Louis, MO, USA) for 3 h. AM-37, ST-36, AM-13, or AM-14 were added for 30 min followed by 100 nM BA₁ for 2 min. Cell extracts were made as described previously (16), and 600 μg of protein extract was immunoprecipitated with 4 μg anti-phosphotyrosine antibody (Becton Dickenson, USA). The immunoprecipitates were fractionated using a 4–20% polyacrylamide gel (Novex, San Diego, CA, USA). Proteins were transferred to a nitrocellulose membrane and incubated with 2 μg anti-EGFR or anti-ERK antibody (Cell Signaling Technologies, Danvers, MA, USA). After washing the blot, it was incubated with enhanced chemiluminescence detection reagent (Thermo Scientific) for 5 min and exposed to Biomax XAR film (Carestream, Rochester, NY, USA). The band intensity was determined using a Kodak image station 440 densitometer. Alternatively, 20 μg of protein extract was loaded onto polyacrylamide gels and after transfer to nitrocellulose, the blot was probed with anti-PY₁₀⁶⁴-EGFR, anti-EGFR, anti-PY₂⁰⁴-ERK, or anti-ERK (Cell Signaling Technologies, Danvers, MA, USA).

**Proliferation**

The proliferation of NSCLC cells was investigated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay as described previously (16). NCI-H727, H1299, and H1975 cells were placed in SIT medium and varying concentration of AM-37, ST-36, AM-13, or AM-14 added. After 2 days, 0.1% MTT solution (15 μl) was added. After 4 h, DMSO (150 μl) was added and the absorbance at 570 nm was determined.

**Statistical Analysis**

The results are expressed as the mean ± SD. Statistical significance of differences was performed by a one-way or two-way
The ability of varying concentrations of AM-37 (●), ST-36 (◼), AM-13 (▴), and AM-14 (▾) to inhibit specific $^{125}$I-BA1 binding was investigated using (A) BB$_{1R}$-, (B) BB$_{2R}$-, and (C) BRS-3-transfected NCI-H1299 cells. The mean value ± SD of three determinations each repeated in duplicate is shown. (D) The structure of AM-37 and ST-36 is shown. (E) The structure of AM-13 and AM-14 is shown; *indicates the optically active site.
repeated measures of variance. The binding curves were drawn using PRISM.

RESULTS

Receptor Binding
The ability of the small molecules to bind to BB-R, BB-R, and BRS-3 was investigated. AM-37 (R-enantiomer) inhibited specific $^{125}$I-BA1 binding to BB-R, BB-R, and BRS-3 in a dose-dependent manner with $K_i$ values of 3.6, 1.4, and 5.5 µM, respectively (Figure 1). ST-36 (S-enantiomer) inhibited specific $^{125}$I-BA1 binding to BB-R, BB-R, and BRS-3 with $K_i$ values of 27, 6.9, and 10.8 µM, respectively (Figure 1). In contrast, AM-13 (R-enantiomer) and AM-14 (S-enantiomer) inhibited specific $^{125}$I-BA1 binding to BB-R, BB-R, and BRS-3 with $K_i > 20$ µM. The results indicate that AM-37 and ST-36 bind to BB-R, BB-R, and BRS-3 with greater affinity than does AM-13 and AM-14.

The specificity of binding was investigated. Table 1 shows that BA1 bound with high affinity ($K_i = 0.002$, 0.0005, and 0.0044 µM) to BB-R, BB-R, and BRS-3. AM-37, ST-36, AM-13, and AM-14 inhibited specific $^{125}$I-BA1 binding ($K_i = 1.4$, 6.9, 27, and 45 µM) to BB-R. ST-36 inhibited specific $^{125}$I-BA1 binding ($K_i = 7.9$ and 10.8 µM) to BB-R and BRS-3, respectively. AM-13 and AM-14 bind with low affinity to BB-R and BRS-3 ($K_i > 100$ µM and >100 µM, respectively).

Cytosolic Ca$^{2+}$

The ability of the small molecules to function as BB-R, BB-R, and BRS-3 antagonists was investigated. Addition of 10 nM BA1 to NCI-H1299 cells transfected with BB-R increased the cytosolic Ca$^{2+}$ from 160 to 178 nM within seconds (Figure 2A). The response was transient and returned to baseline after 1 min. Addition of 30 µM AM-37 to NCI-H1299 cells transfected with BB-R had no effect on the basal cytosolic Ca$^{2+}$ but blocked the increase in cytosolic Ca$^{2+}$ caused by BA1 (Figure 2B). Addition of 30 µM AM-14 had no effect of basal cytosolic Ca$^{2+}$ but partially blocked the increase caused by 10 nM BA1 (Figure 2C). Table 2 shows that AM-37 and AM-14 significantly inhibited the ability of BA1 to increase cytosolic Ca$^{2+}$ after addition to NCI-H1299 cells transfected with BB-R. Addition of 10 nM BA1 to NCI-H1299 cells transfected with BB-R increased the cytosolic Ca$^{2+}$ from 160 to 186 nM (Figure 2D). Addition of 30 µM ST-36 to NCI-H1299 cells transfected with BB-R had no effect on the basal cytosolic Ca$^{2+}$ but blocked the increase in cytosolic Ca$^{2+}$ caused by BA1 (Figure 2E). Addition of 30 µM AM-14 had no effect of basal cytosolic Ca$^{2+}$ but partially blocked the increase caused by 10 nM BA1 (Figure 2F). Table 2 shows that ST-36 and AM-14 significantly decreased the ability of 10 nM BA1 to elevate cytosolic Ca$^{2+}$ in NCI-H1299 cells transfected with BB-R. Addition of 10 nM BA1 to NCI-H1299 cells transfected with BRS-3 increased the cytosolic Ca$^{2+}$ from 170 to 194 nM (Figure 2G). Addition of 30 µM ST-36 to NCI-H1299 cells transfected with BRS-3 had no effect on the basal cytosolic Ca$^{2+}$ but blocked the increase in cytosolic Ca$^{2+}$ caused by BA1 (Figure 2H). Addition of 30 µM AM-13 had no effect of basal cytosolic Ca$^{2+}$ but partially blocked the increase caused by 10 nM BA1 (Figure 2I). Table 2 shows that ST-36 and AM-13 significantly decreased the ability of 10 nM BA1 to elevate cytosolic Ca$^{2+}$ in NCI-H1299 cells transfected with BRS-3. The results indicate that AM-37 and ST-36 are antagonists for BB-R, BB-R, and BRS-3. In contrast, AM-13 and AM-14 are weak antagonists for the BBR family.

The specificity of AM-37, ST-36, AM-13, and AM-14 was investigated. 10 nM neurotensin (NT) or 5 µg/ml ionomycin (ION) strongly increased the cytosolic Ca$^{2+}$ in NSCLC cells. AM-37 or ST-36 had no effect on the ability of NT to increase cytosolic Ca$^{2+}$ in NSCLC cells. AM-13 or AM-14 had no effect on the ability of ION to increase Ca$^{2+}$ in NSCLC cells. Therefore, AM-36 and ST-37 are antagonists for the BBR but not the NTR.

Tyrosine Phosphorylation
The ability of the small molecules to impair EGFR transactivation was investigated. Previously, we found that the BB-R and BRS-3 regulate EGFR tyrosine phosphorylation (13, 16). Figure 3 shows that addition of 100 nM BA1 to NCI-H1299 cells transfected with BB-R increased significantly the EGFR tyrosine phosphorylation to 326%. If the cells were pretreated with 10 µM AM-37 or ST-36, addition of BA1 had little effect. In contrast, if the cells were treated with 10 µM AM-13, BA1 increased strongly EGFR tyrosine phosphorylation. Similarly, BA1 addition to NCI-H1299 cells transfected with BB-R increased ERK tyrosine phosphorylation to 277%. This increase in ERK tyrosine phosphorylation was decreased significantly in the cells pretreated with AM-37 or ST-36 but not AM-13. Similarly, AM-14 had little effect on EGFR or ERK tyrosine phosphorylation (data not shown). The results indicate that AM-37 and ST-36 antagonize the ability of the BB-R to regulate tyrosine phosphorylation of the EGFR and ERK. Similar transactivation results were obtained for NSCLC cells transfected with BB-R or BRS-3 (data not shown).

Proliferation
The ability of the small molecules to inhibit lung cancer proliferation was investigated. AM-37 inhibited NCI-H1299 proliferation in a dose-dependent manner. Figure 4 shows that AM-37 had little effect at 3 µM but strongly inhibited proliferation at 30 µM. The IC$_{50}$ for AM-37 was 16 µM. Similarly, ST-36 had an IC$_{50}$ of 22 µM, whereas AM-14 was less potent (IC$_{50}$ > 50 µM).

TABLE 1 | Binding to lung cancer cells transfected with human bombesin receptors.

| Ligand | $K_i$, µM |
|--------|-----------|
| BA1    | 0.002 ± 0.0002, 0.0005 ± 0.0001, 0.004 ± 0.0003 |
| AM-37  | 3.6 ± 0.5, 1.4 ± 0.2, 5.5 ± 0.6 |
| ST-36  | 7.9 ± 0.9, 6.9 ± 0.3, 10.8 ± 0.9 |
| AM-13  | >100, 27 ± 4, >100 |
| AM-14  | >100, 45 ± 8, >100 |

The mean value ± SD of four determinations is indicated. The structure of bombesin agonist 1 is (D-Tyr$^6$, β-Ala$^9$), Phe$^{13}$, Nle$^{14}$)BB$^{6–14}$. BRS-3, bombesin receptor subtype-3.
The ability of (a) 10 nM bombesin agonist 1 (BA1) and 10 nM neurotensin (NT), (B) 30 µM AM-37 followed by 10 nM BA1 and 10 nM NT, and (C) 30 µM AM-14 followed by 10 nM BA1 and 5 µg/ml ionomycin (ION) to increase cytosolic Ca\(^{2+}\) was determined as a function of time after the addition to NCI-H1299 cells transfected with BB1R. The ability of (D) 10 nM BA1 and 10 nM NT, (E) 30 µM ST-36 followed by 10 nM BA1 and 10 nM NT, and (F) 30 µM AM-14 followed by 10 nM BA1 and 5 µg/ml ION to increase cytosolic Ca\(^{2+}\) was determined as a function of time after the addition to NCI-H1299 cells transfected with BB2R. The ability of (G) 10 nM BA1 and 10 nM NT, (H) 30 µM ST-36 followed by 10 nM BA1 and 10 nM NT, and (I) 30 µM AM-13 followed by 10 nM BA1 and 5 µg/ml ION to increase cytosolic Ca\(^{2+}\) was determined as a function of time after the addition to NCI-H1299 cells transfected with bombesin receptor subtype-3. This experiment is representative of three others.

### Table 2

| Addition | Increase in cytosolic Ca\(^{2+}\), nM |
|----------|--------------------------------------|
|          | BB1R  | BB2R  | BRS-3  |
| BA1, 10 nM | 18.5 ± 1.1 | 26.3 ± 1.7 | 24.4 ± 2.3 |
| BA1 + AM-37, 30 µM | 1 ± 0.6 | 0 | 0 |
| BA1 + ST-36, 30 µM | 0 | 0 | 0 |
| BA1 + AM-13, 30 µM | 7 ± 0.8 | 5 ± 0.6 | 2 ± 0.3 |
| BA1 + AM-14, 30 µM | 6 ± 0.6 | 6 ± 0.5 | 3 ± 0.4 |

The initial increase in the cytosolic Ca\(^{2+}\) after addition of BA1 to lung cancer cells containing BB1R, BB2R, or BRS-3 is indicated. Addition of small molecules significantly inhibited (\(p < 0.01\); by ANOVA) the ability of BA1 to increase cytosolic Ca\(^{2+}\). This experiment is representative of three others.

The specificity of the small molecules was investigated. Table 3 shows that AM-37, ST-36, AM-13, and AM-14 (50 µM) inhibited significantly the proliferation of NCI-H727 cells, which have mRNA for BB1R, BB2R, and BRS-3. In contrast, AM-37, ST-36, AM-13, and AM-14 had little effect on NCI-H1975 cells, which lack BB1R, BB2R, and BRS-3. These results indicate that the BBR is essential for AM-37, ST-36, AM-13, or AM-14 to inhibit cancer cellular proliferation.

### DISCUSSION

While NSCLC patients are traditionally treated with combination chemotherapy, the 5-year survival rate is only 16% (17). Some NSCLC patients (13%) have L858R EGFR mutations, and these patients respond to TKI such as gefitinib or erlotinib; however, secondary EGFR mutations can occur such as T790M resulting in TKI resistance (18). Numerous GPCR are expressed in lung cancer cell lines and biopsy specimens. BB1R mRNA is expressed in 46–67% of the lung cancer cell lines examined (19). BB2R mRNA is present in 81% of the NSCLC cell lines examined (20). Using autoradiographic techniques,
BRS-3 binding sites were detected in 40% of the lung cancer biopsy specimens examined (21). The EGFR is abundant on NSCLC (approximately 100,000 EGFR/cell), whereas BBR are present on most native NSCLC cells (approximately 2,000 BBR/cell) (22).

Addition of GRP to NSCLC cells causes transactivation of the EGFR (23). The effects of GRP on NSCLC tyrosine phosphorylation of the EGFR are impaired by gefitinib, a TKI, and PD176252, a peptoid BB2R antagonist. Because the ERK and EGFR tyrosine phosphorylation caused by GRP was impaired by marimastat, GM6001 and antibodies to TGFα, matrix metalloproteases may regulate the cellular shedding of TGFα from NSCLC cells. The TGFα may then bind to the EGFR causing its tyrosine phosphorylation. The results indicate that the BB2R regulates EGFR transactivation in NSCLC cells.

The BB2R regulates EGFR transactivation (16). The increase in EGFR and ERK tyrosine phosphorylation caused by NMB addition to NSCLC cells was impaired by PD168368, a BB1R peptoid antagonist, as well as gefitinib. The increase in EGFR tyrosine phosphorylation caused by NMB was impaired by N-acetyl cysteine (NAC), an antioxidant, or tiron, a superoxide scavenger. NMB increased reactive oxygen species (ROS) in NSCLC cells, and the increase was inhibited by Tiron. It remains to be determined if the ROS impair protein tyrosine phosphatases in NSCLC cells, which remove phosphate from the P-EGFR. Activation of BRS-3 with BA1 increased EGFR and ERK tyrosine phosphorylation (13). The increase in EGFR tyrosine phosphorylation caused by BA1 is impaired by NAC, tiron, and diphenyleneiodonium, an inhibitor of NADPH oxidase enzymes.

ML-18 is a small molecule that prefers BRS-3 relative to BB1R or BB2R (24). ML-18, an S-enantiomer, inhibits 125I-BA1 binding to BRS-3, BB2R, and BB1R with IC50 values of 4.8, 16, and >100 µM, respectively, whereas the R-enantiomer EMY-98 is inactive. ML-18 is a BRS-3 antagonist, which inhibits the ability of BA1 to increase cytosolic Ca2+, increase ERK and EGFR tyrosine phosphorylation (24). Also, ML-18 inhibited NSCLC growth and increased the cytotoxicity of gefitinib.

His107 is important for BRS-3 to bind antagonists with high affinity (25). Tyr 101 of the BB2R is important for binding of non-peptide antagonists (26). Similarly, this Tyr is conserved in the BB1R and BRS-3. It remains to be determined if this Tyr is essential for binding of AM-37 to the BB2R, BB1R, or BRS-3. ST-36, which is an S-enantiomer, inhibited specific 125I-BA1 binding to BB2R, BB1R, and BRS-3 with IC50 values of 7.9, 6.9, and 10.8 µM, respectively. It is surprising that AM-37, which is the R-enantiomer, binds with slightly higher affinity to BBR than does ST-36. Previously, the BB2R was found to prefer PD168,368, which is an S-isomer, relative to the R-isomer (27).

(D-Arg1, D-Trp5,7,9, Leu11)substance P (SP) is an inhibitor of signal transduction and growth of SCLC cells (28). (D-Arg1, D-Trp5,7,9, Leu11)SP impaired the ability of BB, vasopressin, or bradykinin to increase cytosolic Ca2+ and ERK activity. (D-Arg1, D-Trp5,7,9, Leu11)SP decreased SCLC growth in vitro, and (D-Arg1, D-Trp5,7,9, Leu11)SP has a unique tertiary structure in two type IV non-standard turns, which juxtapose the N- and C-terminal adjacent to one another (29). Due to this unique structure (D-Arg1, D-Trp5,7,9, Leu11)SP may be able to interact with multiple GPCR. In contrast, AM-37 and ST-36 are small molecules that have a different structure from that of (D-Arg1, D-Trp5,7,9, Leu11)SP.

AM-37 and ST-36 inhibited the proliferation of NSCLC cells such as NCI-H1299 and H727, which have BB2R, BB1R, or BRS-3.
**TABLE 3** | MTT proliferation assay using human lung cancer cell lines.

| Addition   | % proliferation |
|------------|-----------------|
|            | NCI-H727 | NCI-H1975 |
| None       | 100 ± 5  | 100 ± 6   |
| AM-37, 50 µM | 13 ± 1a  | 103 ± 5   |
| ST-36, 50 µM | 30 ± 3a  | 95 ± 5    |
| AM-13, 50 µM | 67 ± 4a  | 89 ± 5    |
| AM-14, 50 µM | 64 ± 3a  | 88 ± 6    |

The ability of AM-37, ST-36, AM-13, and AM-14 to inhibit non-small cell lung cancer growth was determined using NCI-H727, which express BB1R, BB2R, and bombesin receptor subtype-3 and H1975 cells, which do not express BB1R. The mean value ± SD of eight determinations is indicated. This experiment is representative of two others; *p < 0.05, **p < 0.01, relative to no additions by ANOVA. Using a test for normality, the data points had a Gaussian distribution.

**FIGURE 4** | MTT assay. The ability of varying doses of AM-37 (○), ST-36 (●), and AM-14 (▲), to inhibit the proliferation of NCI-H1299 cells is shown. The mean value ± SD of eight determinations is indicated. This experiment is representative of two others.

In contrast, AM-37 and ST-36 have little effect on NSCLC cell line NCI-H1975, which lacks BB1R, BB2R, and BRS-3. It remains to be determined if AM-37 or ST-36 are synergistic with gefitinib at inhibiting the growth of NSCLC. A goal is to identify GPCR antagonists, which potentiate the action of TKI in NSCLC patients.

**CONCLUSION**

AM-37 and ST-36 are small molecules, which bind to the BB1R, BB2R, and BRS-3. Because AM-37 and ST-36 inhibit the ability of BA1 to increase cytosolic Ca^{2+} as well as increase EGFR and ERK tyrosine phosphorylation, they function as BB1R, BB2R, and BRS-3 antagonists. A particular advantage of AM-37 and ST-36 is that they will inhibit the growth of NSCLC cells if they have BB1R, BB2R, or BRS-3.

**AUTHOR CONTRIBUTIONS**

TM and SM were responsible for the receptor binding studies. TM and NT were responsible for the cell culture and calcium experiments. TM, PM, and IR-A were responsible for the transactivation and growth experiments. ML was responsible for the synthesis of the small molecules. TM and RJ were responsible for the writing of the manuscript.
ACKNOWLEDGMENTS

The authors thank Drs. M. Nicklaus, E. Lacivita, D. Venzon, and M. Peach for helpful discussions.

REFERENCES

1. Moreno P, Ramos-Alvarez I, Moody TW, Jensen RT. Bombesin related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment. Expert Opin Ther Targets (2016) 20:1055–73. doi:10.1517/14728222.2016.1164964
2. Ramos-Alvarez I, Moreno P, Mantey SA, Nakamura T, Nuche-Berenguer B, Moody TW, et al. Insights into bombesin receptors and ligands: high-lighting recent advances. Peptides (2015) 72:128–44. doi:10.1016/j.peptides.2015.04.026
3. Mantey SA, Weber HC, Sainz E, Akerson M, Ryan RR, Pradhan TK, et al. Discovery of a high affinity radioligand for the human orphan receptor, bombesin receptor subtype3, which demonstrates it has a unique pharmacology compared to other mammalian bombesin receptors, J Biol Chem (1997) 272:26062–71. doi:10.1074/jbc.272.21.26062
4. Majumdar ID, Weber HC. Appetite-modifying effects of bombesin receptor subtype-3 agonists. Handb Exp Pharmacol (2012) 209:405–32. doi:10.1007/978-3-642-47163-3_19
5. Moody TW, Meraili Z. Bombesin-like peptides and associated receptors within the brain: distribution and behavioral implications. Peptides (2004) 25:51–20. doi:10.1016/j.peptides.2004.02.012
6. Moody TW, Cort CR, Gazdar AF, Carney DN, Minna JD. High levels of intracellular bombesin characterize human small cell lung carcinoma. Science (1981) 214:1246–8. doi:10.1126/science.6272398
7. Wood SM, Wood JR, Ghatei MA, Lee YC, O’Shaughnessy D, Bloom SR. Substance P, a novel potent inhibitor of signal transduction and growth factors. Peptides (2015) 72:128–44. doi:10.1016/j.peptides.2015.03.018
8. Wood SM, Wood JR, Ghatei MA, Lee YC, O’Shaughnessy D, Bloom SR. Bombesin, somatostatin and neurotensin-like immunoreactivity in bronchial carcinoma. J Clin Endocrinol Metab (1981) 53:1310–2. doi:10.1210/jcem-53-6-1310
9. Cuttitta F, Carney DN, Mulshine J, Moody TW, Fedorko J, Fischler A, et al. Bombesin-like peptides can function as autocrine growth factors in human small cell lung cancer. Nature (1985) 316:823–6. doi:10.1038/316823a0
10. Giaccone G, Battey J, Gazdar AF, Oie H, Draoui M, Moody TW. Neurotensin B is present in lung cancer cell lines. Cancer Res (1991) 52:2723–6.
11. Moody TW, Mantey P, Jensen RT. Neuropeptides as lung cancer growth factors. Peptides (2015) 72:106–11. doi:10.1016/j.peptides.2015.03.018
12. Moody TW, Nuche-Berenguer B, Nakamura T, Jensen RT. EGFR transacti-
13. Moody TW, Sancho V, Di Florio A, Nuche-Berenguer B, Mantey SA, Jensen RT, Battey JF, Spindel ER, Benya RV. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling and functions in normal and disease states. Pharmacol Rev (2008) 60:1–42. doi:10.1124/pr.107.071018
14. Moody TW, Sancho V, Di Florio A, Nuche-Berenguer B, Mantey SA, Jensen RT. Bombesin receptor subtype-3 agonists stimulate the growth of lung cancer cells and increase EGFR receptor tyrosine phosphorylation. Peptides (2011) 32:1677–84. doi:10.1016/j.peptides.2011.06.011
15. Lacivita E, Scheptokin IA, Stama ML, Kirpotina LN, Colabufo NA, Perrone R, et al. Novel 3-(1H-indol-3-yl)-2-[3-(4-methoxyphenyl)ureido] propanamides as selective agonist of human formyl-peptide receptor2. Bioorg Med Chem (2015) 23:3913–24. doi:10.1016/j.bmc.2014.12.007
16. Chang Y, Prussof WH. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50% inhibition (I50) of an enzymatic reaction. Biochem Pharmacol (1973) 22:3099–108. doi:10.1016/S0006-2952(73)90196-2
17. Kaufman J, Horn L, Carbone D. Molecular biology of lung cancer. In: DeVita W Jr, Lawrence T, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott, Williams & Wilkins (2011). p. 789–98.
18. Lopes GL, Vattimo EF, Castro Junior GD. Identifying activation mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancer. J Bras Pneumol (2015) 41:365–75. doi:10.1590/S1806-3713201500004331
19. Corjajy M, Dobrzanski DJ, Way JM, Viallet J, Shapira H, Worland P, et al. Two distinct bombesin receptor subtypes are expressed and functional in human lung carcinoma cells. J Biol Chem (1991) 266:18771–9.
20. Siegfried JM, Krishnamachary N, Gauthier D, Oswald C, Heitz J, Shriver SP. Evidence for autocrine actions of neuromedin B and gastrin-releasing peptide in non-small cell lung cancer. Palm Pharmacol Ther (1999) 12:291–302. doi:10.1016/ppt.1999.02:10
21. Reubi JC, Wengen S, Schmutzli-Mauer J, Scher JC, Gugger M. Bombesin receptor subtypes in human cancers: detection with the universal radioligand [125I]-(D-Tyr6, β-Ala11, Phe13, Nle14)-bombesin(6-14). Clin Cancer Res (2002) 8:1139–46.
22. Moody TW, Lee M, Kris RM, Bellot F, Bepler G, Oie H, et al. Lung carcinoid cell lines have bombesin-like peptides and EGFR receptors. J Cell Biochem (1990) 43:139–47. doi:10.1002/jcb.240430205
23. Thomas SM, Grandis JR, Wentzel AL, Gooding WE, Lui VWY, Siegfried JM. Gastrin-releasing peptide receptor mediates activation of the epidermal growth factor receptor in lung cancer cells. Neoplasia (2006) 7:426–31. doi:10.1593/neo.04454
24. Moody TW, Mantey SA, Moreno P, Nakamura T, Lacivita E, Leopoldo M, et al. ML-18 is a non-peptide bombesin receptor subtype-3 antagonist which inhibits lung cancer growth. Peptides (2015) 64:53–61. doi:10.1016/j.peptides.2014.12.005
25. Nakamura T, Ramos-Alvarez I, Jordanskaia T, Moreno P, Mantey SA, Jensen RT. Molecular basis for high affinity and selectivity of peptide antagonists, Bantag-1, for the orphan BB3 receptor. Biochem Pharmacol (2016) 115:64–76. doi:10.1016/j.bcp.2016.06.013
26. Carriero A, Lacivita E, Danilo Belvisi B, Calandrino R, Mastrorilli P, Gallo V, et al. Structural determinants in the binding of BB2 receptor ligands: in silico, x-ray and NMR studies in PD176252 analogues. Curr Top Med Chem (2017) 17:1599–610. doi:10.2174/15680266176661014102459
27. Ashwood V, Brownhill V, Higginbottom M, Horwell D, Hughes J, Lewthwaite A, et al. PD176252-the first high affinity non-peptide gastrin-releasing peptide (BB2) receptor antagonist. Bioorg Med Chem Lett (1996) 6:2389–94. doi:10.1016/S0960-894X(96)00462-4
28. Seckl MJ, Higgins T, Widner F, Rezenguiri E, [D-Arg1, D-Trp5,7,9, Leu11] substance P, A novel potent inhibitor of signal transduction and growth in vitro and in vivo in small cell lung cancer cells. Cancer Res (1997) 57:51–4.
29. Jeire DA, Kumar M, Hu WS, Sinnett-Smith J, Rezenguiri EA. The lipid-associated 3D structure of SPA, a broad-spectrum neuropetide antagonist with anticancer properties. Biophys J (2006) 91:4478–89. doi:10.1529/ biophysj.106.089292

FUNDING

This research was supported by the intramural programs of the NCI and NIDDK of the NIH.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.

Copyright © 2017 Moody, Tashakkori, Mantey, Moreno, Ramos-Alvarez, Leopoldo and Jensen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.